Cryopreservation of human vascular umbilical cord cells under good manufacturing practice conditions for future cell banks

Journal of Translational Medicine

Cora Lueders⁴  Roland Hetzer³  Wolfgang Henrich¹  Anne Reichardt³  Gerno Schmiedeknecht²  Kati Kebbel²  Bianca Polchow³ 

[1] Charité-Universitätsmedizin Berlin, Department of Obstetrics, Augustenburger Platz 1, 13353, Berlin, Germany;Fraunhofer Institute for Cell Therapy and Immunology IZI, Department of Cell Engineering/GMP, Perlickstr. 1, 04103, Leipzig, Germany;German Heart Institute Berlin, Department of Cardiothoracic and Vascular Surgery, Laboratory for Tissue Engineering, Augustenburger Platz 1, 13353, Berlin, Germany;Laboratory for Tissue Engineering German Heart Institute Berlin, Augustenburger Platz 1, Berlin, D-13353, Germany

关键词: Cell banking;    Cryopreservation;    Good manufacturing practice (GMP);    Vascular human umbilical cord cells;   

Others  :  1205983
DOI  :  10.1186/1479-5876-10-98

 received in 2012-01-04, accepted in 2012-05-16,  发布年份 2012

【 摘 要 】

Background

In vitro fabricated tissue engineered vascular constructs could provide an alternative to conventional substitutes. A crucial factor for tissue engineering of vascular constructs is an appropriate cell source. Vascular cells from the human umbilical cord can be directly isolated and cryopreserved until needed. Currently no cell bank for human vascular cells is available. Therefore, the establishment of a future human vascular cell bank conforming to good manufacturing practice (GMP) conditions is desirable for therapeutic applications such as tissue engineered cardiovascular constructs.

Materials and methods

A fundamental step was the adaption of conventional research and development starting materials to GMP compliant starting materials. Human umbilical cord artery derived cells (HUCAC) and human umbilical vein endothelial cells (HUVEC) were isolated, cultivated, cryopreserved (short- and long-term) directly after primary culture and recultivated subsequently. Cell viability, expression of cellular markers and proliferation potential of fresh and cryopreserved cells were studied using trypan blue staining, flow cytometry analysis, immunofluorescence staining and proliferation assays. Statistical analyses were performed using Student’s t-test.

Results

Sufficient numbers of isolated cells with acceptable viabilities and homogenous expression of cellular markers confirmed that the isolation procedure was successful using GMP compliant starting materials. The influence of cryopreservation was marginal, because cryopreserved cells mostly maintain phenotypic and functional characteristics similar to those of fresh cells. Phenotypic studies revealed that fresh cultivated and cryopreserved HUCAC were positive for alpha smooth muscle actin, CD90, CD105, CD73, CD29, CD44, CD166 and negative for smoothelin. HUVEC expressed CD31, CD146, CD105 and CD144 but not alpha smooth muscle actin. Functional analysis demonstrated acceptable viability and sufficient proliferation properties of cryopreserved HUCAC and HUVEC.

Conclusion

Adaptation of cell isolation, cultivation and cryopreservation to GMP compliant starting materials was successful. Cryopreservation did not influence cell properties with lasting impact, confirming that the application of vascular cells from the human umbilical cord is feasible for cell banking. A specific cellular marker expression profile was established for HUCAC and HUVEC using flow cytometry analysis, applicable as a GMP compliant quality control. Use of these cells for the future fabrication of advanced therapy medicinal products GMP conditions are required by the regulatory authority.

【 授权许可】

   
2012 Polchow et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]World Health Organizationhttp://www.who.int/cardiovascular_diseases/en/ webcite
• [2]Hoenig MR, Campbell GR, Rolfe BE, Campbell JH: Tissue-engineered blood vessels: alternative to autologous grafts? Arterioscler Thromb Vasc Biol 2005, 25:1128-1134.
• [3]Cannegieter SC, Rosendaal FR, Briet E: Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994, 89:635-641.
• [4]Schmidt D, Hoerstrup SP: Tissue engineered heart valves based on human cells. Swiss Med Wkly 2006, 136:618-623.
• [5]Schoen FJ: Heart valve tissue engineering: quo vadis? Curr Opin Biotechnol 2011.
• [6]Steinhoff G: The regenerating heart- hope for children with congenital heart defects. Kinderkrankenschwester 2006, 25:47-50.
• [7]Breymann C, Schmidt D, Hoerstrup SP: Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev 2006, 2:87-92.
• [8]Kadner A, Hoerstrup SP, Tracy J, Breymann C, Maurus CF, Melnitchouk S, Kadner G, Zund G, Turina M: Human umbilical cord cells: a new cell source for cardiovascular tissue engineering. Ann Thorac Surg 2002, 74:S1422-1428.
• [9]Hoerstrup SP, Kadner A, Breymann C, Maurus CF, Guenter CI, Sodian R, Visjager JF, Zund G, Turina M: Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann Thorac Surg 2002, 74:46-52. discussion 52
• [10]Filova E, Straka F, Mirejovsky T, Masin J, Bacakova L: Tissue-engineered heart valves. Physiol Res 2009, 58(Suppl 2):S141-158.
• [11]Mendelson K, Schoen FJ: Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 2006, 34:1799-1819.
• [12]Kadner A, Zund G, Maurus C, Breymann C, Yakarisik S, Kadner G, Turina M, Hoerstrup SP: Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothorac Surg 2004, 25:635-641.
• [13]Tsuruda T, Imamura T, Hatakeyama K, Asada Y, Kitamura K: Stromal cell biology–a way to understand the evolution of cardiovascular diseases. Circ J , 74:1042-1050.
• [14]Hoffman-Kim D, Maish MS, Krueger PM, Lukoff H, Bert A, Hong T, Hopkins RA: Comparison of three myofibroblast cell sources for the tissue engineering of cardiac valves. Tissue Eng 2005, 11:288-301.
• [15]Schaefermeier PK, Cabeza N, Besser JC, Lohse P, Daebritz SH, Schmitz C, Reichart B, Sodian R: Potential cell sources for tissue engineering of heart valves in comparison with human pulmonary valve cells. ASAIO J 2009, 55:86-92.
• [16]Lueders C: Tissue engineering of cardiovascular structures: Application of fresh and cryopreserved human umbilical cord cells. Zeitschrift für Herz- Thorax- und Gefäßchirurgie 2003, 17:198-204.
• [17]Sodian R, Lueders C, Kraemer L, Kuebler W, Shakibaei M, Reichart B, Daebritz S, Hetzer R: Tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann Thorac Surg 2006, 81:2207-2216.
• [18]Walker CW, Pye BG: The length of the human umbilical cord: a statistical report. Br Med J 1960, 1:546-548.
• [19]Rubinstein P: Cord blood banking for clinical transplantation. Bone Marrow Transplant 2009, 44:635-642.
• [20]Garcia J: Allogeneic unrelated cord blood banking worldwide: an update. Transfus Apher Sci , 42:257-263.
• [21]UK Stem Cell Bankhttp://www.ukstemcellbank.org.uk/ webcite
• [22]Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive: 2001/83/EC and Regulation (EC) No 726/2004..
• [23]Voltz-Girolt C, Celis P, Boucaumont M, D'Apote L, Pinheiro MH, Papaluca-Amati M: The advanced therapy classification procedure. Overview of experience gained so far. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz , 54:811-815.
• [24]Belardelli F, Rizza P, Moretti F, Carella C, Galli MC, Migliaccio G: Translational research on advanced therapies. Ann Ist Super Sanita , 47:72-78.
• [25]Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use.
• [26]Sensebe L, Bourin P, Tarte K: Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011, 22:19-26.
• [27]Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
• [28]Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997, 64:295-312.
• [29]Ulrich-Merzenich G, Metzner C, Bhonde RR, Malsch G, Schiermeyer B, Vetter H: Simultaneous isolation of endothelial and smooth muscle cells from human umbilical artery or vein and their growth response to low-density lipoproteins. In Vitro Cell Dev Biol Anim 2002, 38:265-272.
• [30]van der Loop FT, Schaart G, Timmer ED, Ramaekers FC, van Eys GJ: Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol 1996, 134:401-411.
• [31]Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells, The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
• [32]Pinchuk IV, Mifflin RC, Saada JI, Powell DW: Intestinal mesenchymal cells. Curr Gastroenterol Rep , 12:310-318.
• [33]Covas DT, Panepucci RA, Fontes AM, Silva WA, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA: Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008, 36:642-654.
• [34]Schugar RC, Chirieleison SM, Wescoe KE, Schmidt BT, Askew Y, Nance JJ, Evron JM, Peault B, Deasy BM: High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol 2009, 2009:789526.
• [35]de Llano JJ Martin, Fuertes G, Torro I, Garcia Vicent C, Fayos JL, Lurbe E: Birth weight and characteristics of endothelial and smooth muscle cell cultures from human umbilical cord vessels. J Transl Med 2009, 7:30. BioMed Central Full Text